Rhythm Biosciences Limited

#ICYMI Earlier this year we contributed a book chapter to serve as a valuable resource for general practitioners looking to incorporate genetic tools into their daily practice. "Polygenic Risk Scores: A Conceptual Overview to Add PRS to Your Clinical Toolbox" is now available in the "Implementation of Personalized Precision Medicine" book (January 2025). At Rhythm Biosciences, we're committed to advancing not only our diagnostic technologies like geneType™ and ColoSTAT® but also providing educational resources that help healthcare providers implement these innovations effectively. This chapter offers practical guidance on understanding and utilising polygenic risk score, a powerful tool that can significantly enhance preventative care and early detection strategies. Interested in learning how genetic risk assessment can transform your practice? Have a read or connect with our team to learn more about our comprehensive genetic risk assessment platform https://lnkd.in/g5C598gZ  #personalisedmedicine #genetics #precisionhealth #medtech #innovation  

A reminder to register for our Extraordinary General Meeting on Monday morning. It's another opportunity to hear about our strategic direction, recent milestones, and future growth plans in the cancer diagnostics space. Register here https://lnkd.in/gUWwtkBa #shareholders #investors #ASX #cancerdiagnostics #medtech

We were honoured to participate as a vendor at the 3rd Annual Celebrating Women in the Queen City on Monday evening. This incredible night of networking and empowerment featured the live "Be Amazing" podcast, discussing women working in multifamily and beyond. A big thank you to the organiser Celia Smart for bringing together an amazing group of community leaders to share their journeys and inspire women working in multifamily and entering the workforce with Dress for Success Charlotte. Erika Spaeth, PhD Meghan Bee. #networking #event #geneType #queencity

#BTS at booth 231 at the ACMG - American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting this week. Our team has been engaging with healthcare professionals, researchers, and industry partners passionate about transforming cancer diagnostics. These conversations reinforce why we do what we do - creating simple, affordable diagnostic solutions for early cancer detection that could save lives. A huge thank you to everyone who stopped by so far to learn more about our journey, including our recent commercial milestone with geneType™ products and our plans for global growth. Looking forward to turning these connections into collaborations that will help shape the future of cancer diagnostics. David Atkins Jackson Jones Erika Spaeth, PhD #ACMG2025 #cancerdiagnostics #networking #innovation #medtech

Big news: Rhythm has recorded its first commercial sales of geneType™ products since acquiring the business in December 204. This milestone comes just months after restoring Genetype's commercial capabilities, and we're confident in an attractive sales growth profile ahead, driven by: - A strong pipeline of potential enterprise customers - Support from influential Key Opinion Leaders - High-quality clinical evidence and peer-reviewed publications - A roadmap of product improvements - Opportunities for geographic expansion "It is most pleasing to have crossed this threshold, with Rhythm from here on being able to record commercial sales revenues," said Dr David Atkins, our Managing Director and CEO. This is just the beginning - we expect growing revenues from the geneType™ portfolio, with ColoSTAT® commercial revenues to follow in the next financial year. Read the full news here: https://lnkd.in/gJE8giph #cancerdiagnostics #medtech #ASX #biotech #precisionmedicine

Delighted to announce Todd Perkinson has joined Rhythm Biosciences as our new Chief Financial Officer. Todd brings exceptional financial leadership experience, most recently as CEO of AdNeo Limited (ASX: AD1) where he delivered impressive EBITDA and NPAT improvements while securing a $2.6M capital raise. With a proven track record in business transformation across healthcare, technology and financial services sectors, Todd's expertise in financial restructuring and strategic growth will be invaluable as we continue our mission to revolutionise cancer diagnostics. His experience guiding the $100M sale of Vault Intelligence and orchestrating a $1B healthcare merger aligns perfectly with our ambitious growth plans. #newappointment #CFO #leadership #medtech #cancerdiagnostics 

Did you know colorectal cancer is the #1 cause of cancer deaths in men under 50 and #2 in women under 50? March is National Colorectal Cancer Awareness Month — learn more about your screening options and take a short quiz by visiting getscreened.org.

Revolutionising early disease detection – Join Rhythm Biosciences at the 2025 ACMG Annual Clinical Genetics Meeting in LA next week. Visit our team at Booth #231 to discover how our innovative solutions are transforming early disease detection. Specifically, geneTypeTM – our advanced polygenic risk score multi-test platform which delivers unprecedented precision in assessing individual risk for serious conditions including breast, colorectal, and ovarian cancers, enabling truly personalised preventative care strategies. Our specialists Erika Spaeth, PhD David Atkins and Jackson Jones will be available to discuss how geneTypeTM enables clinicians to support early disease detection, improve risk stratification and personalised healthcare that empower patients to take control of their health. We welcome you to drop by our booth or message us privately to schedule a specific time with our team. #ACMG2025 #innovation #cancerdiagnostics #personalisedhealth #earlydetection

I had the privilege of presenting at the Australian Polygenic Implementation Research Summit on a topic I'm deeply passionate about – addressing ancestry considerations in polygenic risk scoring. Polygenic risk scores (PRS) offer tremendous potential as a population health tool, helping us stratify disease risk for conditions like breast cancer, coronary artery disease, and type 2 diabetes. However, a critical challenge persists – most PRS models have been developed using predominantly European ancestry data, creating potential disparities in their application across diverse populations. The good news? We don't need to wait for perfect solutions. At Rhythm Biosciences Limited, we're implementing practical approaches that can be applied today: Leveraging SNPs with similar allele frequencies across genetic ancestries   Using European weights with proper calibration and mean adjustment   Developing ancestry-specific weights for more personalised risk assessment Our data shows these methods significantly improve PRS performance across diverse populations. While predictive performance may attenuate somewhat in non-European populations, these calibrated scores still provide valuable risk stratification.  The ultimate goal remains developing truly personalised PRS based on an individual's unique ancestry composition. As we continue building more diverse genetic databases, we're implementing these solutions to ensure the benefits of precision medicine can be realised by all populations. What approaches are you seeing in your work to address genetic diversity in precision medicine tools? I'd love to know. #precisionmedicine #genetics #polygehicriskscores #diseasesrisk #healthequity  

Colorectal cancer is not just a disease of ageing. A major global study has found that colorectal cancer is surging among young people, with Australia having one of the highest increases.  This highlights an urgent need for earlier detection and better screening options. At Rhythm Biosciences, we're committed to advancing early cancer detection technology to help change this trajectory. Understand more about this important study via Health Report Australian Broadcasting Corporation (ABC) https://lnkd.in/d7rFj_EU   #cancer #cancerresearch #colorectalcancer #healthinnovation